Diana Karpman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1062802/publications.pdf

Version: 2024-02-01

100	6,567	53751	64755
papers	citations	45 h-index	79 g-index

105	105	105	5736
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Crosstalk between the reninâ€“angiotensin, complement and kallikreinâ€“kinin systems in inflammation. Nature Reviews Immunology, 2022, 22, 411-428.	10.6	61
2	IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection. Frontiers in Immunology, 2022, 13, 807959.	2.2	2
3	A role for complement blockade in kidney transplantation. , 2022, , .		2
4	A link between KrÃ¼ppel-like factor 4, complement activation, and kidney damage. Kidney International, 2022, 102, 14-16.	2.6	1
5	Isolation and Characterization of Shiga Toxin-Associated Microvesicles. Methods in Molecular Biology, 2021, 2291, 207-228.	0.4	1
6	Annexin Induces Cellular Uptake of Extracellular Vesicles and Delays Disease in Escherichia coli O157:H7 Infection. Microorganisms, 2021, 9, 1143.	1.6	10
7	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 690821.	2.2	13
8	Extracellular vesicles in renal inflammatory and infectious diseases. Free Radical Biology and Medicine, 2021, 171, 42-54.	1.3	15
9	Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit. Toxins, 2020, 12, 449.	1.5	12
10	Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor. Frontiers in Cellular and Infection Microbiology, 2020, 10, 212.	1.8	16
11	Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism. Scientific Reports, 2019, 9, 14362.	1.6	12
12	Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. EBioMedicine, 2019, 47, 319-328.	2.7	28
13	Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatric Nephrology, 2019, 34, 11-30.	0.9	230
14	Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	0
15	Aliskiren inhibits renin-mediated complementÂactivation. Kidney International, 2018, 94, 689-700.	2.6	53
16	Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli â€“ An Anti-thrombotic Mechanism in the Kidney. EBioMedicine, 2017, 16, 302-311.	2.7	2
17	Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis. Kidney International, 2017, 91, 96-105.	2.6	42
18	C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles. Journal of the American Society of Nephrology: JASN, 2017, 28, 2472-2481.	3.0	30

#	Article	IF	Citations
19	Extracellular vesicles in renal disease. Nature Reviews Nephrology, 2017, 13, 545-562.	4.1	238
20	Orphan drug policies and use in pediatric nephrology. Pediatric Nephrology, 2017, 32, 1-6.	0.9	22
21	Haemolytic uraemic syndrome. Journal of Internal Medicine, 2017, 281, 123-148.	2.7	108
22	Microvesicle Involvement in Shiga Toxin-Associated Infection. Toxins, 2017, 9, 376.	1.5	29
23	Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coliâ€“Infected Mice. Journal of Immunology, 2016, 197, 1276-1286.	0.4	19
24	Complement contributes to theÂpathogenesis of Shiga toxinâ€“associated hemolytic uremic syndrome. Kidney International, 2016, 90, 726-729.	2.6	11
25	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	0.9	445
26	Shiga Toxinâ€“Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cellâ€“Derived Microvesicles in Hemolytic Uremic Syndrome. Journal of Immunology, 2015, 194, 2309-2318.	0.4	65
27	A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles. PLoS Pathogens, 2015, 11, e1004619.	2.1	95
28	Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Advances in Experimental Medicine and Biology, 2015, 865, 19-42.	0.8	48
29	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	0.9	95
30	Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatric Nephrology, 2014, 29, 2225-2228.	0.9	101
31	The Combined Role of Galactose-Deficient IgA1 and Streptococcal IgAâ€“Binding M Protein in Inducing IL-6 and C3 Secretion from Human Mesangial Cells: Implications for IgA Nephropathy. Journal of Immunology, 2014, 193, 317-326.	0.4	47
32	Enterohemorrhagic Escherichia coli Pathogenesis and the Host Response. Microbiology Spectrum, 2014, 2, .	1.2	42
33	Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy. Journal of Immunology, 2013, 191, 2184-2193.	0.4	59
34	Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatric Nephrology, 2013, 28, 155-158.	0.9	35
35	Ouabain Protects against Shiga Toxinâ€“Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL. Journal of the American Society of Nephrology: JASN, 2013, 24, 1413-1423.	3.0	37
36	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation, 2013, 28, 2899-2907.	0.4	25

#	Article	IF	Citations
37	A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 188, 2030-2037.	0.4	46
38	Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrology Dialysis Transplantation, 2012, 27, 3669-3674.	0.4	17
39	The Antimicrobial Peptide Cathelicidin Protects Mice from Escherichia coli O157:H7-Mediated Disease. PLoS ONE, 2012, 7, e46476.	1.1	68
40	Phenotypic Expression of ADAMTS13 in Glomerular Endothelial Cells. PLoS ONE, 2011, 6, e21587.	1.1	19
41	Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliâ€“induced hemolytic uremic syndrome. Blood, 2011, 117, 5503-5513.	0.6	163
42	Kinin system activation in vasculitis*. Acta Paediatrica, International Journal of Paediatrics, 2011, 100, 950-957.	0.7	2
43	Intestinal damage in enterohemorrhagic Escherichia coli infection. Pediatric Nephrology, 2011, 26, 2059-2071.	0.9	40
44	IgA nephropathy associated with a novel N-terminal mutation in factor H. European Journal of Pediatrics, 2011, 170, 107-110.	1.3	17
45	Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. Pediatric Blood and Cancer, 2011, 56, 762-766.	0.8	25
46	Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrology Dialysis Transplantation, 2011, 26, 3399-3403.	0.4	33
47	Cross-Reactive Protection against Enterohemorrhagic Escherichia coli Infection by Enteropathogenic E. coli in a Mouse Model. Infection and Immunity, 2011, 79, 2224-2233.	1.0	30
48	Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. Current Topics in Microbiology and Immunology, 2011, 357, 105-136.	0.7	51
49	Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatric Nephrology, 2010, 25, 87-96.	0.9	34
50	Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4 Variants May Protect against Severe Urinary Tract Infection. PLoS ONE, 2010, 5, e10734.	1.1	90
51	Pathogen Specific, IRF3-Dependent Signaling and Innate Resistance to Human Kidney Infection. PLoS Pathogens, 2010, 6, e1001109.	2.1	68
52	Pathophysiology of Typical Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2010, 36, 575-585.	1.5	59
53	Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy. Nephrology Dialysis Transplantation, 2010, 25, 3434-3436.	0.4	8
54	Tissue Deposits of IgA-Binding Streptococcal M Proteins in IgA Nephropathy and Henoch-SchÃ¶nlein Purpura. American Journal of Pathology, 2010, 176, 608-618.	1.9	60

#	Article	IF	Citations
55	Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin. Journal of Immunology, 2009, 182, 7906-7915.	0.4	50
56	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology, 2009, 24, 687-696.	0.9	315
57	Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatric Nephrology, 2009, 24, 447-458.	0.9	17
58	Successful thrombolysis of neonatal bilateral renal vein thrombosis originating in the IVC. Pediatric Nephrology, 2009, 24, 2069-2071.	0.9	12
59	The contact/kinin and complement systems in vasculitis. Apmis, 2009, 117, 48-54.	0.9	10
60	A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Molecular Immunology, 2009, 46, 2236-2243.	1.0	39
61	Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome. PLoS ONE, 2009, 4, e6990.	1.1	113
62	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2008, 45, 95-105.	1.0	136
63	Shiga Toxin-Mediated Disease in MyD88-Deficient Mice Infected with Escherichia coli O157:H7. American Journal of Pathology, 2008, 173, 1428-1439.	1.9	41
64	Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood, 2008, 111, 5307-5315.	0.6	128
65	Reduced Tollâ€Like Receptor 4 Expression in Children with Asymptomatic Bacteriuria. Journal of Infectious Diseases, 2007, 196, 475-484.	1.9	113
66	Inherited Susceptibility to Acute Pyelonephritis: A Family Study of Urinary Tract Infection. Journal of Infectious Diseases, 2007, 195, 1227-1234.	1.9	86
67	Factor H dysfunction contributes to platelet activation in hemolytic uremic syndrome (HUS). Molecular Immunology, 2007, 44, 191-192.	1.0	0
68	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Molecular Immunology, 2007, 44, 1835-1844.	1.0	73
69	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2007, 44, 3971.	1.0	0
70	A Genetic Basis of Susceptibility to Acute Pyelonephritis. PLoS ONE, 2007, 2, e825.	1.1	85
71	Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 2007, 138, 651-662.	1.2	84
72	Anguish over angiopathy: Hemolytic uremic syndrome. Clinical Immunology, 2007, 122, 135-138.	1.4	0

#	Article	IF	Citations
73	ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. European Journal of Pediatrics, 2007, 166, 249-257.	1.3	25
74	Uropathogenic Escherichia coli as a model of hostâ€“parasite interaction. Current Opinion in Microbiology, 2006, 9, 33-39.	2.3	98
75	A common origin of the 4143insA ADAMTS13 mutation. Thrombosis and Haemostasis, 2006, 96, 3-6.	1.8	74
76	Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood, 2006, 108, 167-176.	0.6	166
77	Platelet Activation in Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 128-145.	1.5	47
78	Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 113-120.	1.5	91
79	Mutation analysis and clinical implications of von Willebrand factorâ€“cleaving protease deficiency. Kidney International, 2003, 63, 1995-1999.	2.6	83
80	Contact-system activation in children with vasculitis. Lancet, The, 2002, 360, 535-541.	6.3	35
81	Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Current Paediatrics, 2002, 12, 569-574.	0.2	14
82	Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatric Nephrology, 2002, 17, 201-211.	0.9	35
83	Human renal epithelial cells express iNOS in response to cytokines but not bacteria. Kidney International, 2002, 61, 444-455.	2.6	24
84	Correct evaluation of renal glomerular filtration rate requires clearance assays. Pediatric Nephrology, 2002, 17, 847-851.	0.9	33
85	Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood, 2001, 97, 3100-3108.	0.6	127
86	Fimbriae, Transmembrane Signaling, and Cell Activation. Journal of Infectious Diseases, 2001, 183, S47-S50.	1.9	36
87	Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Pediatric Research, 2001, 50, 163-171.	1.1	180
88	Interleukinâ€8 Receptor Deficiency Confers Susceptibility to Acute Pyelonephritis. Journal of Infectious Diseases, 2001, 183, S56-S60.	1.9	63
89	The â€˜innateâ€™ host response protects and damages the infected urinary tract. Annals of Medicine, 2001, 33, 563-570.	1.5	41
90	Interleukin 8 Receptor Deficiency Confers Susceptibility to Acute Experimental Pyelonephritis and May Have a Human Counterpart. Journal of Experimental Medicine, 2000, 192, 881-890.	4.2	175

#	Article	IF	Citations
91	Innate Defences and Resistance to Gram Negative Mucosal Infection. , 2000, 485, 9-24.		11
92	Multimeric Î±-Lactalbumin from Human Milk Induces Apoptosis through a Direct Effect on Cell Nuclei. Experimental Cell Research, 1999, 246, 451-460.	1.2	96
93	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. Journal of Urology, 1998, 159, 2185-2192.	0.2	60
94	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. Journal of Urology, 1998, , 2185-2192.	0.2	2
95	Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies. Infection and Immunity, 1998, 66, 636-644.	1.0	161
96	Bernardâ€Soulier syndrome Karlstad: Trp 498â†'Stop mutation resulting in a truncated glycoprotein Ibî± that contains part of the transmembranous domain. British Journal of Haematology, 1997, 98, 57-63.	1.2	28
97	von Willebrand Factor Mediates Increased Platelet Retention in Recurrent Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1997, 78, 1456-1462.	1.8	19
98	Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney International, 1996, 49, 190-199.	2.6	25
99	Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatric Nephrology, 1995, 9, 694-699.	0.9	124
100	EnterohemorrhagicEscherichia coliPathogenesis and the Host Response. , 0, , 381-402.		1